Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.

Literature DB >> 28398313

Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.

Ken Garber.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2017 PMID： 28398313 DOI： 10.1038/nbt0417-297a

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

5 in total

1. Predictive biomarkers for checkpoints, first tests approved.

Authors: Ken Garber
Journal: Nat Biotechnol Date: 2015-12-09 Impact factor: 54.908

2. The role of microsatellite instability testing in management of colorectal cancer.

Authors: Frank A Sinicrope
Journal: Clin Adv Hematol Oncol Date: 2016-07

3. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245

4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245

5. Epitope landscape in breast and colorectal cancer.

Authors: Neil H Segal; D Williams Parsons; Karl S Peggs; Victor Velculescu; Ken W Kinzler; Bert Vogelstein; James P Allison
Journal: Cancer Res Date: 2008-02-01 Impact factor: 12.701

5 in total

6 in total

1. Loxo TRK inhibitor data wows oncologists.

Authors: Elie Dolgin
Journal: Nat Biotechnol Date: 2017-08-08 Impact factor: 54.908

2. High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging.

Authors: Shanshan He; Ruchir Bhatt; Carl Brown; Emily A Brown; Derek L Buhr; Kan Chantranuvatana; Patrick Danaher; Dwayne Dunaway; Ryan G Garrison; Gary Geiss; Mark T Gregory; Margaret L Hoang; Rustem Khafizov; Emily E Killingbeck; Dae Kim; Tae Kyung Kim; Youngmi Kim; Andrew Klock; Mithra Korukonda; Alecksandr Kutchma; Zachary R Lewis; Yan Liang; Jeffrey S Nelson; Giang T Ong; Evan P Perillo; Joseph C Phan; Tien Phan-Everson; Erin Piazza; Tushar Rane; Zachary Reitz; Michael Rhodes; Alyssa Rosenbloom; David Ross; Hiromi Sato; Aster W Wardhani; Corey A Williams-Wietzikoski; Lidan Wu; Joseph M Beechem
Journal: Nat Biotechnol Date: 2022-10-06 Impact factor: 68.164

Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.

1. Predictive biomarkers for checkpoints, first tests approved.

2. The role of microsatellite instability testing in management of colorectal cancer.

3. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

5. Epitope landscape in breast and colorectal cancer.

1. Loxo TRK inhibitor data wows oncologists.

2. High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging.

3. Awakening immunity against cancer: a 2017 primer for clinicians.

Review 4. Immuno-Oncology: Emerging Targets and Combination Therapies.

Review 5. Machine Learning and Radiogenomics: Lessons Learned and Future Directions.

6. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers.